Necitumumab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

Human IgG1 (F126L)-Kappa

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of necitumumab, a fully human IgG1 antibody directed against the epidermal growth factor receptor (EGFR, UniProt P00533). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the EGFR extracellular domain as its target, the biosimilar reproduces the antigen-binding specificity of the originator, making it useful as a reference antibody in EGFR-focused assays. Typical research applications include EGFR-binding and ligand-blockade studies, isotype- and pathway-matched controls, competition experiments against other anti-EGFR antibodies, ADCC and antibody-drug-conjugate (ADC) development workflows, and characterisation of EGFR-expressing cell lines. It is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low-endotoxin option (<0.5 EU/mg) suitable as an in-vivo-grade standard, and is available in bulk milligram-to-gram quantities to support screening, assay development, and preclinical model work. EGFR (ErbB1/HER1) is a single-pass transmembrane receptor tyrosine kinase of the ErbB family. Ligands such as EGF and TGF-alpha bind its extracellular region, driving receptor homo- or heterodimerisation (including with HER2/HER3), trans-autophosphorylation of the intracellular kinase domain, and activation of downstream RAS-RAF-MEK-ERK, PI3K-AKT, and STAT signalling that governs proliferation, survival, and differentiation. EGFR is frequently overexpressed, amplified, or mutated in epithelial malignancies, making it a central oncology target. Antibodies binding the ligand-binding extracellular domain block ligand engagement and receptor activation and can additionally engage immune effector mechanisms via their Fc region, providing a rationale for both signalling-blockade and effector-based research approaches.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

Detects human EGFR

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.